Report of Foreign Issuer (6-k)
June 25 2018 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2018
001-37353
(Commission File Number)
BIONDVAX PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
14 Einstein St.
Ness Ziona
Israel 7414002
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
In connection
with BiondVax Pharmaceuticals Ltd.’s (hereinafter, the “Registrant”, the “Company”, or “BiondVax”)
previous Current Report on form 6-K, dated June 19, 2017, regarding entering into a Finance Contract with the European Investment
Bank, or EIB, for the finance of up to 20 million Euros and up to 50% of the Company’s expected cost of developing and marketing
the Company’s product candidate, M-001, used as a primer in combination with existing seasonal or pandemic vaccines, providing
multi-season and multi-strain protection against all human influenza virus strains, on June 19, 2018, BiondVax issued a press release
announcing it had received its first €6M tranche disbursement from the EIB. A copy of this press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: June 25, 2018
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024